Mass cytometry reveals immune atlas of urothelial carcinoma

Immunotherapy has emerged as a robust clinical strategy for cancer treatment. PD1/PD-L1 inhibitors have been used as second-line therapy for urothelial carcinoma due to the high tumor mutational burden. Despite the efficacy of the treatment is significant, the response rate is still poor. The tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qing, Zhang, Wenlong, Lin, Tingsheng, Lu, Wenfeng, He, Xin, Ding, Yuanzhen, Chen, Wei, Diao, Wenli, Ding, Meng, Shen, Pingping, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210814/
https://www.ncbi.nlm.nih.gov/pubmed/35725444
http://dx.doi.org/10.1186/s12885-022-09788-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210814/
https://www.ncbi.nlm.nih.gov/pubmed/35725444
http://dx.doi.org/10.1186/s12885-022-09788-7

Ejemplares similares